Medical device group Creo Medical said Wednesday that it had entered into a distribution agreement with Diagmed Healthcare to seed the UK market with the company's advance energy platform and speedboat products and help roll out its UK Clinical Education Program. Under the terms of the agreement, Diagmed would collaborate with Creo over an 18-month period, purchasing a minimum quantity of Creo's advance energy platforms and Speedboat products. Diagmed would also accelerate the roll out of Creo's Clinical Education Programme in the UK. Once the seeding phase is complete, Diagmed and Creo are expected to enter into a further agreement providing Diagmed exclusivity over the distribution of Creo's 'Croma' advanced energy electrosurgery platform and Creo's suite of GI devices in the UK. 'This agreement is the next significant milestone in the commercialisation of our lead product, Speedboat RS2,' said Craig Gulliford, Creo's Chief Executive Officer. 'Our products are rapidly gaining traction in the endoscopic field and with Diagmed as our UK partner, their expertise and knowledge in this important market will prove invaluable to Creo as we build our reputation worldwide.' At 8:26am: (LON:CREO) Creo Medical Group Plc share price was +1.5p at 129.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.